What types of policy changes does Capital Blue Cross issue?

Capital Blue Cross regularly publishes coverage updates including prior authorization requirement changes, billing code additions or deletions, plan-type coverage modifications, and clinical policy revisions. PolicyChanges.app monitors these notices and summarizes the impact for providers.

How often does Capital Blue Cross update its policies?

Capital Blue Cross typically releases policy bulletins on a rolling basis throughout the year. Our system checks for new updates daily and adds them to this feed as soon as they are identified.

How many Capital Blue Cross policy changes are tracked here?

This page currently tracks 25 documented Capital Blue Cross policy changes. New items are added as they are identified.

What should I do when Capital Blue Cross changes a prior authorization policy?

Review each change's effective date and action-required notes. Update your billing and clinical workflows before the effective date to avoid claim denials. Each policy detail page on PolicyChanges.app includes a plain-English summary and action items.

Capital Blue Cross Policy Changes & Prior Auth Updates

We track 25 documented policy changes from Capital Blue Cross across PA. Each entry includes an AI-generated plain-English summary, effective date, affected billing codes, and a direct link to the original Capital Blue Cross notice. Use the related links below to narrow results by specialty or state, or sign up for a free daily alert to receive new Capital Blue Cross updates automatically.

High impact
AB2026-05-004 Pharmacy updates
Capital Blue Cross·Effective Jul 1, 2026
Capital Blue Cross is updating their formularies effective July 1, 2026, adding 12-13 newly marketed drugs (many requiring prior authorization and quantity limits), expanding prior authorization requirements to 26 existing medications, and implementing new quantity limits on HIV/AIDS medications and other drugs.
High impact
AB2026-05-001 Updates and new information
Capital Blue Cross·Effective Jul 1, 2026
Capital Blue Cross is transitioning from Avalon to direct contracts with independent laboratories and implementing EviCore's Clinical Guidelines for Lab Management Program version 2.0.2026. This affects all laboratory billing with new medical policy enforcement through claims adjudication and introduces 44 new clinical guidelines while retiring 13 existing ones.
High impact
AB2026-06-004 Medical policies
Capital Blue Cross·Effective Jul 1, 2026
Capital Blue Cross has updated medical policies with new prior authorization requirements for two specialty injectable drugs (Loargys and Exdensur) effective July 1, 2026, and revised policies for 40+ specialty injectable drugs effective August 1, 2026. Multiple medical policies have also removed specific procedure codes that will now be managed by EviCore.
High impact
AB2026-06-001 Updates and new information
Capital Blue Cross·Effective Jul 1, 2026
Capital Blue Cross is implementing multiple changes including a new claim rejection code C1167I for misrouted claims (effective August 1, 2026), transitioning closed-claim letters to electronic format, covering environmental lead investigations for CHIP members, and removing preauthorization requirements for certain genetic testing codes.
High impact
AB2026-05-006 Medical policies
Capital Blue Cross·Effective Jun 1, 2026
Capital Blue Cross is implementing major changes to medical specialty injectable policies and multiple medical policies. A new drug Exdensur will require prior authorization, over 30 injectable medications will have revised policies, and new prior authorization requirements are being added for bio-engineered skin substitutes and other procedures.
High impact
AB2026-05-005 Reminders
Capital Blue Cross·Effective Jun 1, 2026
Capital Blue Cross issued a comprehensive administrative bulletin with multiple policy updates including provider data attestation requirements, MUE claims editing enhancements, expanded breast cancer screening coverage including biopsies, CAQH attestation reminders, and hemophilia factor billing system updates.
High impact
AB2026-03-001 Updates and new information
Capital Blue Cross·Effective May 1, 2026
Capital Blue Cross implemented multiple changes including postponed electronic appeals submissions, new preauthorization requirements for several procedure codes effective May 1, 2026, expanded cardiology and musculoskeletal programs through TurningPoint, and new medical policies for CTA imaging, genetic counseling telehealth services, and various surgical procedures.
High impact
AB2026-04-004 Medical policies
Capital Blue Cross·Effective May 1, 2026
Capital Blue Cross is implementing new prior authorization requirements for three new specialty injectable drugs (Yartemlea, Lunsumio Velo, Rybrevant Faspro) effective May 1, 2026, and revising prior authorization requirements for dozens of existing specialty injectables effective June 1, 2026. The C9399 temporary code will now require prior authorization for many drugs previously covered without authorization.
High impact
AB2026-04-001 Updates and new information
Capital Blue Cross·Effective May 1, 2026
Capital Blue Cross is implementing major changes including mandatory electronic appeals submission through Availity Essentials (May 1), required CAS codes on COB claims (June 1), and mandatory 11-digit NDCs for all drug claims (June 1). Multi-factor authentication is now required for the Prime MPS GatewayPA portal.
High impact
AB2026-03-005 Medical policies
Capital Blue Cross·Effective Apr 1, 2026
Capital Blue Cross has implemented new prior authorization requirements for specialty injectable medications and medical procedures. Key changes include PA requirements for new drug Itvisma (J3590), power wheelchair accessories (E0986), and radiofrequency ablation of thyroid tumors (60660, 60661).
High impact
AB2026-01-003 Medical policies
Capital Blue Cross·Effective Mar 1, 2026
Capital Blue Cross is implementing new prior authorization requirements for multiple specialty injectable medications and biosimilars, including new drugs Keytruda Qlex and Grafapex, plus updating medical policies for numerous existing medications. Several procedure codes will no longer require prior authorization, and some medical policies are being retired.
High impact
AB2026-02-003 Medical policies
Capital Blue Cross·Effective Mar 1, 2026
Capital Blue Cross has updated multiple medical policies effective March 1, 2026 and April 1, 2026, including new prior authorization requirements for medical specialty injectables (delegated to Prime MPS), new PA requirement for Blenrep drug (J9999 code), and revised criteria for numerous injectable medications, medical devices, and diagnostic procedures. Medical specialty injectable PA requests must now be submitted through Prime MPS GatewayPA Portal instead of Capital Blue Cross directly.
High impact
AB2026-03-004 Reminders
Capital Blue Cross·Effective Mar 1, 2026
Capital Blue Cross reminds providers that clinical documentation for concurrent review of continued inpatient stays must be submitted within specified timeframes. Failure to submit documentation on time may result in claim denials for ongoing inpatient services.
High impact
AB2026-02-001 Updates and new information
Capital Blue Cross·Effective Feb 23, 2026
Capital Blue Cross is implementing major changes to appeals processes, requiring electronic submission through Availity Essentials starting February 23, 2026, with mail/fax submissions ending April 1, 2026. Additionally, anatomical modifiers will be required for radiology procedures starting April 1, 2026, and several medical policy updates take effect March 1, 2026.
High impact
AB2026-01-002 Reminders
Capital Blue Cross·Effective Jan 1, 2026
Effective January 1, 2026, Capital Blue Cross is transferring management of preauthorization for specialty injectable medications to Prime Therapeutics. Providers must now obtain preauthorizations for specialty injectables through Prime's portal at GatewayPa.com instead of the previous system.
High impact
AB2026-04-003 Reminders
Capital Blue Cross·Effective Jan 1, 2026
Capital Blue Cross issued multiple reminders including new preauthorization requirements for specialty injectable medications through Prime Therapeutics effective January 1, 2026, requirements to update provider data in CMS's National Plan and Provider Enumeration System, and expansion of shared administrative services with I.B. Abel Inc. through The Loomis Company.
Medium impact
AB2026-05-002 Medicare only
Capital Blue Cross·Effective Jun 1, 2026
Capital Blue Cross Medicare Advantage plans will require preauthorization for 5 new injection codes starting July 1, 2026, while removing preauthorization requirements for 8 medical equipment and imaging codes starting June 1, 2026. The policy also provides important guidance on CMS RADV audit compliance and updated forms.
Medium impact
AB2026-06-003 Reminders
Capital Blue Cross·Effective Jun 1, 2026
Capital Blue Cross clarified that CPT 77332 (treatment device) should NOT be billed separately for HDR gynecologic brachytherapy procedures because it is already bundled into insertion codes CPT 57155 and 57156. While CPT 77332 remains on the prior authorization list, requests will not be approved when submitted with these HDR procedures.
Medium impact
AB2026-06-002 Quality information
Capital Blue Cross·Effective Jun 1, 2026
Capital Blue Cross updated HEDIS quality measure requirements for three diabetes-related screenings: eye exams (EED), glycemic status assessment (GSD), and kidney health evaluation (KED). This administrative bulletin clarifies documentation requirements, acceptable test types, and exclusion criteria for diabetic patients aged 18-85.
Medium impact
AB2026-03-002 Medicare only
Capital Blue Cross·Effective May 1, 2026
Capital Blue Cross updated Prime Therapeutics clinical guidelines for Medicare Advantage plans, adding new HCPCS codes to step therapy requirements and clarifying the 90-day Continuity of Care rule that waives prior authorization for new Medicare Advantage members during their transition period.
Medium impact
AB2026-05-003 Quality information
Capital Blue Cross·Effective May 1, 2026
This administrative bulletin provides updated quality measure guidelines for breast cancer screening, cervical cancer screening, depression screening, and follow-up care for multiple chronic conditions. It emphasizes best practices for documentation, proper use of exclusion codes, and utilization of the Theon system for gap reporting and data submissions.
Medium impact
AB2026-04-002 Medicare only
Capital Blue Cross·Effective Apr 1, 2026
Capital Blue Cross updated Medicare Part D Star measures for 2026, adding new exclusions for Statin Use in Persons with Diabetes (SUPD) that recognize PCSK9 inhibitors and bempedoic acid as alternatives for patients who cannot tolerate statins. Providers must submit specific ICD-10-CM codes annually during in-person or audio/video visits to qualify patients for exclusions from the SUPD measure.
Medium impact
AB2026-03-003 Quality information
Capital Blue Cross·Effective Mar 1, 2026
Capital Blue Cross is continuing HEDIS medical record collection and requires providers to submit requested medical records within 5 business days at no cost. The policy also provides updated guidance on colorectal cancer screening (age 45-75) and all-cause readmission measures.
Medium impact
AB2026-02-002 Reminders
Capital Blue Cross·Effective Feb 1, 2026
Capital Blue Cross has updated provider communication and maintenance processes, requiring organizational changes to be sent to a new dedicated email (notifications@capbluecross.com) and demographic updates to be made through their provider portal tools only, not through Availity's Provider Data Management tool.
Medium impact
AB2026-01-001 Updates and new information
Capital Blue Cross·Effective Jan 1, 2026
Capital Blue Cross launched a redesigned provider website with streamlined navigation and fewer login requirements, released the 2026 Provider Manual online, and announced multiple policy updates including new continuity of care provisions, electronic appeals functionality coming Q1 2026, and updated medical policies for high-tech imaging effective March 1, 2026.

Capital Blue Cross in PA Capital Blue Cross: Allergy & Immunology Capital Blue Cross: Cardiology Capital Blue Cross: Dermatology Capital Blue Cross: Endocrinology All payers

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

AB2026-05-004 Pharmacy updates

AB2026-05-001 Updates and new information

AB2026-06-004 Medical policies

AB2026-06-001 Updates and new information

AB2026-05-006 Medical policies

AB2026-05-005 Reminders

AB2026-03-001 Updates and new information

AB2026-04-004 Medical policies

AB2026-04-001 Updates and new information

AB2026-03-005 Medical policies

AB2026-01-003 Medical policies

AB2026-02-003 Medical policies

AB2026-03-004 Reminders

AB2026-02-001 Updates and new information

AB2026-01-002 Reminders

AB2026-04-003 Reminders

AB2026-05-002 Medicare only

AB2026-06-003 Reminders

AB2026-06-002 Quality information

AB2026-03-002 Medicare only

AB2026-05-003 Quality information

AB2026-04-002 Medicare only

AB2026-03-003 Quality information

AB2026-02-002 Reminders

AB2026-01-001 Updates and new information